Lucentis

US appeals court revives Regeneron's antitrust lawsuit against Novartis
Yahoo/Reuters
Mon, 03/18/24 - 05:09 pm
Novartis
Regeneron
legal
Eylea
Lucentis
antitrust
Novartis, Roche avoid $475M antitrust fine in French appeals court
Fierce Pharma
Mon, 02/20/23 - 12:57 pm
Novartis
Roche
antitrust
Lucentis
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Thu, 01/26/23 - 05:05 pm
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
Endpoints
Thu, 08/25/22 - 07:48 pm
FDA
interchangeability
biosimilars
Lucentis
Roche
Coherus Biosciences
Cimerli
Novartis tips Lucentis to weather the arrival of biosimilar copies in Europe
Biopharma Reporter
Thu, 08/11/22 - 12:30 pm
Novartis
Lucentis
biosimilars
patents
Europe
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
BioPharma Dive
Wed, 08/3/22 - 09:26 pm
Coherus Biosciences
biosimilars
Lucentis
Roche
Cimerli
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Ophthalmology Today
Fri, 06/3/22 - 09:11 am
Biogen
Samsung Bioepis
ranibizumab
ranibizumab-nuna
biosimilars
Roche
Lucentis
retinal disease
FDA approves first biosimilar to top-selling eye drug Lucentis
BioPharma Dive
Mon, 09/20/21 - 10:55 pm
FDA
biosimilars
Lucentis
age-related macular degeneration
Byooviz
Biogen
Samsung Bioepis
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Wed, 08/4/21 - 10:53 am
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
The top 10 drugs losing U.S. exclusivity in 2021
Fierce Pharma
Wed, 03/10/21 - 10:59 pm
patents
Lucentis
Bystolic
Vascepa
Narcan
Brovana
Sutent
Saphris
Amitza
Feraheme
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Thu, 11/19/20 - 10:33 am
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
Roche, already prepping 2021 launch, charts big expansion plans for Lucentis eye implant
Fierce Pharma
Thu, 09/17/20 - 11:04 pm
Roche
macular degeneration
Lucentis
eye implants
wet age-related macular degeneration
Novartis, Roche fined $526M in France for alleged Lucentis marketing missteps
Fierce Pharma
Wed, 09/9/20 - 10:59 am
Novartis
Roche
France
Lucentis
anti-competitive scheme
'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece
Fierce Pharma
Fri, 06/26/20 - 01:08 pm
Novartis
Greece
DOJ
Lucentis
kickbacks
physicians
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis
Xconomy
Wed, 06/24/20 - 10:14 am
AsclepiX Therapeutics
eye disease
Eylea
Lucentis
macular edema
wet age-related macular degeneration
retinal occulsion
AXT107
Biogen signs marketing deal for two ophthalmology biosimilars
Pharmaforum
Thu, 11/7/19 - 10:16 am
Biogen
ophthalmology
biosimilars
Europe
Japan
Samsung Bioepis
SB11
SB15
Lucentis
Eylea
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Endpoints
Tue, 04/2/19 - 12:04 pm
Allergan
abicipar
wet age-related macular degeneration
Lucentis
Molecular Partners
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Thu, 10/25/18 - 11:43 am
Regeneron
Eylea
diabetic retinopathy
Roche
Lucentis
Novartis plans to file for new Lucentis indication in ROP
Pharmaceutical Business Review
Mon, 09/24/18 - 09:39 am
Novartis
Lucentis
ROP
retinopathy of prematurity
Roche, Novartis' Italian heads risk trial for alleged market rigging: sources
Yahoo/Reuters
Fri, 12/8/17 - 10:00 am
Roche
Novartis
Italy
Avastin
Lucentis
marketing manipulation

Pages